New report from the American College of Cardiology/American Heart Association Task Force states 46% of Americans have high blood pressure
CHICAGO – December, 5, 2017 – BIOLIFE4D, a biotech pioneer leveraging advances in tissue engineering to 3D print human organs viable for transplant, today commented on a new report from the American College of Cardiology/American Heart Association (ACA/AHA) Task Force regarding the prevention, detection, evaluation, and management of high blood pressure in adults.
The report recommends that high blood pressure be treated at 130/80 rather than 140/90, meaning that 14% more American adults have high blood pressure than under previous guidelines. Rather than one in three U.S. adults having high blood pressure, the new guidelines say nearly half of our country’s adult population (46%) is now afflicted.
“The new guidelines from the ACA/AHA Task Force are alarming, as it means nearly 150 million adults now suffer from high blood pressure, and likely weren’t aware before that they were in any sort of danger,” said Steven Morris, CEO, BIOLIFE4D. “High blood pressure is the second leading cause of preventable heart disease and stroke death, and is clearly now an American epidemic as almost half of our population is affected.”
High blood pressure, especially chronic or left untreated, can result in significant damage to your body, including your arteries and heart. It can cause coronary artery disease and heart failure, both of which could require a heart transplant. However, with the significant difficulty of securing a heart for transplant – it’s reported only about 5,000 heart transplants occur each year globally despite tens of thousands of people requiring a life-saving heart transplant – it’s more important than ever for the medical community to push through innovation that can solve this need.
“When treated, high blood pressure can potentially be managed and corrected. But what about those with congenital issues, or those without access to consistent medical care? They will likely face heart failure at some point in life, and could face the need for a transplant, which is a daunting thought,” said Morris. “The wait list for a heart transplant already significantly outpaces available donor organs. This unfortunately means that many people already on it won’t even have the opportunity to have a transplant, and even those fortunate to have the transplant have only a 50% change of success beyond 10 years due to rejection of the donor organ or adverse effects from the immunosuppressant therapy required to help prevent rejection. The solution we are working on addresses the excessive waiting list as well as the rejection challenges.”
At BIOLIFE4D we are specifically addressing these challenges by developing a process to 3D bioprint a heart utilizing the patient’s own cells. A patient-specific bioprinted heart viable for transplantation would not require immunosuppressant therapy because it is created utilizing the patient’s own genetic make-up. Heart disease can be prevented for many, but for those that it can’t, we believe our technology can make a difference and save lives.”
BIOLIFE4D has filed a $50 million initial public offering with the Securities and Exchange Commission (SEC) under Regulation A+ equity crowdfunding rules, allowing everyday investors to help the company bring its groundbreaking cardiac tissue regeneration and organ replacement process to market. The “Reg A+” rules, outlined under the 2012 Jumpstart Our Business Startups (JOBS) Act, allow companies to raise up to $50 million in equity from non-accredited investors and others.
To learn more about BIOLIFE4D and to express interest in investing visit https://biolife4d.com/invest/.
BIOLIFE4D is a pioneering biotech company laser focused on leveraging advances in life sciences and tissue engineering to 3D bioprint a viable human heart suitable for transplant – lifesaving technology that gives patients the gift of time. With BIOLIFE4D, a patient-specific, fully functioning heart will be created through 3D bioprinting using the patient’s own cells – eliminating the well-known challenges of organ rejection and long donor waiting lists that plague existing organ transplant methods. Financed through equity crowdfunding, BIOLIFE4D is driving a movement to transform the treatment of heart disease, the leading cause of death among both men and women globally. Learn more and invest at biolife4d.com. Connect with us on social media on Twitter (@BIOLIFE4D), Facebook, LinkedIn, and Instagram.
Although you are currently able to express your interest in investing, BIOLIFE4D Corporation is not yet accepting investments. No money or other consideration is being solicited by the company at this time, and if sent in response, will not be accepted. No offer to buy the securities can be accepted and no part of the purchase price can be received until the offering statement is qualified, and any such offer may be withdrawn or revoked, without obligation or commitment of any kind, at any time before notice of its acceptance given after the qualification date. If you indicate interest, your indication of interest involves no obligation or commitment of any kind.